What Актиферрин Treats: Main Uses and Benefits

Oral iron supplements like Актиферрин are used to address symptoms related to systemic imbalance and are relevant in contexts involving heightened systemic burden. The main goal is to provide supportive relief when symptoms that interfere with daily functioning become more noticeable. This medication is used for easing symptoms associated with conditions involving episodic or fluctuating manifestations, such as Iron-Deficiency Anemia (IDA) and latent iron deficiency.

The medication may assist with managing symptoms, including those related to noticeable physiological strain like persistent fatigue, generalized weakness, dizziness, and reduced concentration. It also addresses the visible tissue-related manifestations of iron depletion, such as brittle nails and excessive hair shedding. This application supports general well-being during symptomatic phases and helps with coping more steadily with symptom fluctuations.

Quick Fact: Relief for Symptoms That Create Noticeable Physiological Strain The medication is relevant for easing symptom clusters that may become intense or disruptive, contributing to improved comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview on Iron Supplements

Who Can and Cannot Use Актиферрин?

The official eligibility profile for Актиферрин (Iron(II) Sulfate/DL-Serine) is defined by regulatory standards for oral iron supplements, with strict rules governing use based on iron status and certain pre-existing conditions.

Contraindications and Restrictions

The medicine is contraindicated in patients with confirmed iron overload syndromes such as hemochromatosis or hemosiderosis, as well as in individuals receiving repeated blood transfusions due to the risk of exacerbating iron levels. It must not be used to treat anemia not caused by iron deficiency, such as hemolytic or aplastic anemia.

Absolute contraindications also include hypersensitivity to any component of the formulation and active gastrointestinal inflammatory diseases like ulcerative colitis or peptic ulceration.

Population-Specific Eligibility

Population	Regulatory Status
Children under 6	Requires mandatory Special Warning regarding the risk of fatal accidental poisoning; must be kept strictly out of reach.
Older Adults	Use requires Caution and confirmation of iron deficiency, as anemia may be due to other underlying causes.
Pregnancy/Lactation	Generally Permitted for use to treat or prevent iron deficiency anemia.

Use is permitted for individuals with diagnosed Iron Deficiency Anemia (IDA) or latent iron deficiency.

Interactions with other medicines and products

The interaction profile for Aktiferrin (Iron(II) Sulfate/DL-Serine) is dominated by pharmacokinetic interactions that alter drug absorption in the gastrointestinal tract. Regulatory labeling specifies formal restrictions and mandatory timing rules to manage these effects.

Drug-Drug Interactions

Co-administration with parenteral iron preparations is strictly contraindicated due to the severe, potentially toxic risk of iron overload. Other agents reduce the absorption and systemic exposure of the iron component, or have their own absorption reduced by iron. These combinations require precise separation of administration time.

Co-administered Product Category	Interaction Outcome & Restriction
Tetracyclines & Fluoroquinolones	Iron reduces antibiotic absorption; must be separated by at least two hours.
Thyroid Hormones (e.g., Levothyroxine)	Iron reduces hormone absorption; must be separated by at least two hours.
Antacids	Increase gastric pH, reducing iron absorption; must be separated by one to two hours.

Drug-Food/Substance Interactions

Iron absorption and exposure are reduced when Aktiferrin is taken with specific dietary components. Food items high in tannins (tea/coffee), phytates (cereals), or phosphates (dairy) are documented to form insoluble iron complexes, thereby lowering iron bioavailability. This profile reflects the necessary constraints for ensuring drug efficacy.

Enhanced Iron Absorption and Delivery

This domain centers on the supply of readily absorbable ferrous iron ( Fe^2+). The presence of lactoferrin promotes this process by maintaining iron solubility in the gut and facilitating its uptake across the intestinal wall via specific transport pathways, promoting the delivery of the mineral substrate to the circulation.

---

Iron Utilization and Hemoglobin Synthesis

Once absorbed, the iron is rapidly transported to the bone marrow where it is incorporated into the protoporphyrin ring to form heme, a critical component of Hemoglobin. This biosynthetic cascade is the core mechanism that leads to the formation of new, functional red blood cells, which contributes to the body's oxygen-carrying capacity.

---

Modulating Systemic Iron Homeostasis

Beyond simple replacement, the lactoferrin component acts in the regulation of systemic iron homeostasis. Its ability to bind iron and exert immunomodulatory effects influences inflammation-driven iron sequestration and dysregulation. This mechanism facilitates the release and utilization of iron throughout the body, contributing to the balanced function of iron-dependent physiological processes.

Administration Protocol

Актиферрин is an oral antianemic preparation taken by mouth, available in solid forms (capsules/tablets) and liquid solution, which dictates its method of intake. The medicine is commonly prescribed to be taken once daily, or in divided doses (up to 2 to 3 times per day) for certain therapeutic goals. Adult dosing for treatment of iron deficiency typically corresponds to a daily elemental iron intake of 100-200 mg. Dosing for children under 12 years of age is calculated based on the child's age and body weight.

Administration Timing and Constraints

The most effective administration timing is on an empty stomach (e.g., 30 minutes before or 2 hours after eating) to promote optimal iron absorption. However, if stomach upset occurs, the dose may be taken with or immediately after food. Intake must be separated by a 2-hour interval from substances known to interfere with iron uptake, including milk, dairy products, coffee, and tea.

Solid forms must be swallowed whole with water and must not be chewed, crushed, or held in the mouth. Treatment duration is established as long-term, requiring administration to continue for several months—typically 3 to 6 months after blood values have normalized—to ensure the full replenishment of the body's iron stores. If a dose is missed, it should be taken when remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped.

Research Evidence / Overview of Studies for Актиферрин

Evidence for Use in Iron-Deficiency Anemia (IDA) and Latent Iron Deficiency

The primary research base for the medicine involves studies for its main approved use in conditions characterized by systemic or functional imbalance related to low iron, such as Iron-Deficiency Anemia (IDA). Studies include Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate oral iron salts, like Ferrous Sulfate, which is the active component of Актиферрин. These studies investigated oral iron therapy against placebo or alternative forms of iron treatment.

Research has primarily examined objective biological measurements known as biomarkers. These study outcomes examined include monitoring changes in Hemoglobin (Hb) levels and Serum Ferritin—which reflects the body's iron stores—over defined time intervals. In addition to blood work, studies also looked at patient-reported outcomes describing perceived discomfort related to physical discomfort, such as scores for fatigue and generalized weakness.

Research reported measurements of increases in iron biomarkers and described changes in symptom evolution in the observed populations following administration of oral iron salts. It is important to remember that these findings describe group patterns and research does not determine whether an individual will respond similarly.

---

Research on the Iron-Serine Combination

Актиферрин contains the amino acid DL-Serine, which has been included because research has explored whether it may influence the absorption of the iron component. Comparative evidence exploring this specific combination is limited and heterogeneous. While some studies reported measurements that suggested differences in the rate of early biomarker changes, the findings were mixed when assessing the long-term measurements against standard iron salts. Overall, this research contributes to the broader evidence landscape but has not consistently provided clear evidence of a long-term benefit for this specific combination that applies to all observed populations.

---

Research Gaps and Remaining Uncertainty

Most key clinical trials are designed for intermediate-term durations (three to six months). Consequently, the follow-up durations were limited in many studies when considering sustained, long-term health outcomes. There is limited information for long-term outcomes regarding the durability of the response. Furthermore, many comparative studies have limited sample sizes, and comparative evidence is lacking for robust, head-to-head RCTs that demonstrate a long-term clinical advantage of the Iron-Serine combination. Because of these factors, certainty remains low regarding the specific, long-term comparative benefits of Актиферрин to other oral iron supplements, and research is ongoing in this area.

Key Studies & References

1. Efficacy of different oral iron compounds and doses in iron deficiency: an overview of systematic reviews
2. Diagnosis and management of iron deficiency anemia: a clinical review

Common questions about Актиферрин (FAQ)

---

Q: What is the difference between Актиферрин drops and capsules?

Актиферрин is available in both solid forms, such as capsules or tablets, and a liquid solution. According to official product information, the liquid or syrup format offers an advantage primarily for infants, toddlers, or individuals who experience difficulty swallowing pills, allowing for flexible administration.

---

Q: Why is serine included in the Актиферрин formulation?

The active ingredients include the amino acid DL-Serine alongside the iron component. The inclusion of Serine is based on studies suggesting it may act as a chelator to influence the absorption of the iron component. The formulation is designed to maximize the therapeutic benefit of the iron.

---

Q: How long does it usually take before I might notice the effects of Актиферрин?

Studies on oral iron products indicate that objective measurements of iron status in the body, such as Hemoglobin and Serum Ferritin levels, generally begin to show changes over a period of several weeks following the start of treatment. Regulatory guidance describes that treatment often requires continuation for several months to ensure the full replenishment of the body’s iron stores.

---

Q: What kind of monitoring (like blood tests) is generally described as necessary while taking Актиферрин?

Research associated with this medicine involves monitoring biological markers to assess the effects of the treatment. These measurements are used to monitor changes in Hemoglobin (Hb) levels and Serum Ferritin, which indicates the body's stored iron status, over defined time intervals.

---

Q: What is the standard method for taking a missed dose (general informational context)?

Official administration instructions describe that if a scheduled dose is missed, the guidance is to take it when remembered. However, if that time is close to when the next dose is due, the missed dose is skipped, and the regular schedule should be resumed.

---

Q: Is Актиферрин available over-the-counter or by prescription?

According to official product documentation, Актиферрин is classified as an antianemic preparation that is available both by prescription and over-the-counter (OTC).

---

Q: Does Актиферрин help with fatigue related to iron deficiency?

Research on oral iron therapy has examined changes in patient-reported outcomes related to discomfort, such as generalized weakness and fatigue. Research reported measurements of increases in iron biomarkers and described changes in symptom evolution in the observed populations.

---

Q: Are there any long-term safety concerns mentioned in official documents about Актиферрин?

Official safety data includes a critical warning that iron-containing products must be stored securely to prevent accidental poisoning in children. Contraindications for the medicine include confirmed iron overload syndromes, which are a safety restriction for use. Research documents also note that follow-up durations for many clinical trials are limited to intermediate-term periods of three to six months.

---

Q: Can Актиферрин be taken with milk?

Official regulatory guidance states that intake of the medicine must be separated by a minimum of a two-hour interval from certain substances. This mandatory separation includes milk and dairy products, which are documented to form insoluble iron complexes that lower iron bioavailability.

---

Q: Are there any specific warnings for people with stomach ulcers regarding Актиферрин?

The official eligibility profile lists absolute contraindications (reasons the drug must not be used). These include active gastrointestinal inflammatory diseases, specifically mentioning peptic ulceration.

---

Q: Is the absorption of iron from Актиферрин affected by Vitamin C?

Pharmacological studies related to oral iron products indicate that administration with Ascorbic Acid, commonly known as Vitamin C, may influence the bioavailability and absorption of the iron component.

---

Q: How does the body generally process the iron from Актиферрин?

The medicine provides ferrous iron, a readily absorbable form, which is absorbed primarily in the gut. Once absorbed, the iron is transported through the body to the bone marrow. There, the iron is incorporated into the protoporphyrin ring to form heme, a component of Hemoglobin that contributes to the body's oxygen-carrying capacity.

---

Q: Is Актиферрин available in a liquid form for people who have trouble swallowing?

Yes, Актиферрин is available as a specialized solution or syrup format. This liquid form is cited in the official product information as being suitable for individuals who may have difficulty swallowing pills, in addition to being used for infants and toddlers.

---

Q: What are the official guidelines regarding the use of Актиферрин for prevention versus treatment of iron deficiency?

The official product information lists the medicine's primary approved use as being for both the treatment and the prevention of iron deficiency anemia. The medicine's administration protocol is defined to support both therapeutic and preventative goals for addressing iron deficiency.

---

Q: Is there information available on the use of Актиферрин during breastfeeding?

The official population-specific eligibility profile, based on regulatory standards, indicates that the use of Актиферрин is generally permitted during lactation (breastfeeding) for the prevention or treatment of iron deficiency anemia.

How to Store and Dispose of Актиферрин

Storage and disposal must strictly follow official regulatory requirements to ensure product stability and safety. The medicine must be stored at a temperature below 25°C (less than 77°F). It is required to store the product in its original container and protect it from light and moisture.

Child Safety and Stability

• Keep out of the reach and sight of children. This is mandatory, as accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age.
• Do not use the medicine after the stated expiration date. The shelf life for the oral solution is typically 2 years.

Disposal Instructions

Unused or expired Aktiferrin must be disposed of according to local pharmaceutical waste regulations. The medicine should not be disposed of via wastewater or household waste, which prevents environmental contamination and misuse.